KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $1.6 million.

  • TherapeuticsMD's Operating Expenses fell 208.21% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 4530.95%. This contributed to the annual value of $6.5 million for FY2024, which is 3362.85% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Operating Expenses is $1.6 million, which was down 208.21% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Operating Expenses peaked at $60.0 million during Q3 2021, and registered a low of -$77.8 million during Q4 2021.
  • For the 5-year period, TherapeuticsMD's Operating Expenses averaged around $8.9 million, with its median value being $2.9 million (2023).
  • Per our database at Business Quant, TherapeuticsMD's Operating Expenses plummeted by 25076.74% in 2021 and then skyrocketed by 12586.57% in 2022.
  • Quarter analysis of 5 years shows TherapeuticsMD's Operating Expenses stood at -$77.8 million in 2021, then surged by 125.87% to $20.1 million in 2022, then plummeted by 89.5% to $2.1 million in 2023, then tumbled by 101.56% to -$33000.0 in 2024, then soared by 5087.88% to $1.6 million in 2025.
  • Its Operating Expenses was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.3 million in Q1 2025.